Product correctly added to cart.

discount label
Vatalanib
View 3D

Biosynth logo

Vatalanib

CAS: 212141-54-3

Ref. 3D-MIA14154

5mgTo inquire
10mgTo inquire
25mgTo inquire
50mgTo inquire
100mgTo inquire
Estimated delivery in United States, on Tuesday 2 Jul 2024

Product Information

Name:
Vatalanib
Synonyms:
  • 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-
  • Cgp 79787
  • N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine
  • N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine
  • Pynasunate
  • Vatalinib
Description:

Vatalanib is a new anti-cancer drug that has been developed to inhibit the production of vascular endothelial growth factor (VEGF). It also inhibits cell factor (CF) and other biological properties. Vatalanib binds to the active site of the enzyme phosphatidylinositol 3-kinase, which is required for cell proliferation and survival. This binding leads to an increase in apoptosis, or programmed cell death, in cancer cells. Vatalanib has been shown to be effective against metastatic colorectal cancer and other solid tumours. The drug is not toxic to normal cells because it inhibits a protein that is required for activation of multiple pathways in these cells.

Brand:
Biosynth
Long term storage:
Notes:

Chemical properties

Molecular weight:
346.8 g/mol
Formula:
C20H15ClN4
Purity:
Min. 95%
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:

Hazard Info

UN Number:
EQ:
Class:
H Statements:
P Statements:
Forbidden to fly:
Hazard Info:
Packing Group:
LQ:

Technical inquiry about: 3D-MIA14154 Vatalanib

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.

* Mandatory fields.
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.

Please see our Cookies Policy for more details or adjust your preferences in "Settings".